Patents by Inventor Zheng Xin Dong

Zheng Xin Dong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210163536
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Application
    Filed: February 3, 2021
    Publication date: June 3, 2021
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Publication number: 20200360483
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: February 3, 2020
    Publication date: November 19, 2020
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, John E. Taylor, Rakesh Datta, Michael DeWitt Culler
  • Publication number: 20200347110
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Application
    Filed: December 20, 2019
    Publication date: November 5, 2020
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Publication number: 20200095281
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: December 4, 2019
    Publication date: March 26, 2020
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • Publication number: 20200017548
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Applicant: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin DONG
  • Publication number: 20190248861
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 15, 2019
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Publication number: 20190062374
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Application
    Filed: November 12, 2018
    Publication date: February 28, 2019
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Publication number: 20180305406
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: July 9, 2018
    Publication date: October 25, 2018
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Publication number: 20180161401
    Abstract: The present invention provides a non-buffered, neutral pH easily prepared, storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition has a non-buffered neutral pH which avoids injection site reactions and is easy to prepare and storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Application
    Filed: July 5, 2016
    Publication date: June 14, 2018
    Inventor: Zheng Xin Dong
  • Publication number: 20180118784
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Application
    Filed: August 29, 2017
    Publication date: May 3, 2018
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
  • Publication number: 20180105557
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 19, 2018
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • Patent number: 9850280
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 26, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Publication number: 20170362275
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 21, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin DONG
  • Publication number: 20170304403
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, John E. TAYLOR, Rakesh DATTA, Michael DeWitt CULLER
  • Patent number: 9777039
    Abstract: The present invention relates to novel somatostatin analogs, dimers thereof, and methods of using the same to treat various diseases. Naturally occurring somatostatins (SSTs), which are also known as somatotropin release-inhibiting factors (SRIFs), have diverse biological effects in many cells and organs 10 throughout the body. They are produced by normal endocrine, gastrointestinal, immune and neuronal cells, as well as by certain tumors (Patel, Y. C, Frontiers in Neuroendocrinology, 20(3): 157-198 (1999); Froidevaux, et al., Biopolymers, 66(3): 161-83 (2002)).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 3, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Eric Ferrandis
  • Patent number: 9758549
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: September 12, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Publication number: 20170240595
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • Patent number: 9731027
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: August 15, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
  • Patent number: 9637531
    Abstract: The present invention relates to compositions, methods and kits for delivery of an IGF-1 protein or a functional fragment or variant, derivative thereof to cells or tissues that express proteoglycans. More specifically, the present invention relates to fusion proteins comprising a heparin binding protein (HB) comprising SEQ ID NO: 1 or SEQ ID NO: 2. Other aspects relate to use of a HB-IGF-1 fusion proteins in methods to deliver IGF-1 to the cartilage for the treatment of a cartilage related disease and disorder in a subject.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: May 2, 2017
    Assignee: The Brigham and Women's Hospital, Inc
    Inventors: Richard T. Lee, Parth Patwari, Francesco Loffredo, James Pancoast, Zheng Xin Dong, Todd Vannelli
  • Patent number: 9603942
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: March 28, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen